ArticlePLOS global public health2023
Diagnostic test accuracy of artificial intelligence in screening for referable diabetic retinopathy in real-world settings: A systematic review and meta-analysis.
Article in PLOS global public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 4 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Describing the Performance and the Infrastructure Requirements of the Existing Artificial Intelligence (AI)-Based Diabetic Retinopathy (DR) Screening Algorithms for Diabetic Patients: an Umbrella Review.Journal of medical systems · 2025Pooled it
- Artificial Intelligence improves follow-up appointment uptake for diabetic retinal assessment: a systematic review and meta-analysis.Eye (London, England) · 2025Pooled it
- Artificial intelligence versus manual screening for the detection of diabetic retinopathy: a comparative systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Trends and hotspots in the field of diabetic retinopathy imaging research from 2000-2023.Frontiers in medicine · 2024Pooled it
- Trial
- The diagnostic accuracy of AI-assisted diabetic retinopathy screening in primary care: a prospective validation study.Scandinavian journal of primary health care · 2026Article
- Trust, mistrust, and the promise of AI in genomics for African populations.American journal of human genetics · 2026Review
- Diabetic retinopathy screening telemedicine-based compared with standard of care : an economic analysis in a pilot experience of Italian healthcare.Acta diabetologica · 2026Article
- Diabetic Retinopathy Detection: AI Models and Approaches.Journal of ophthalmology · 2026Review
- Diagnostic test accuracy of teleretinal screening for cytomegalovirus retinitis among people living with HIV: A systematic review and meta-analysis.PLOS global public health · 2026Article
- Diabetic Retinopathy Screening Among Federally Qualified Health Center Patients Using Point-of-Care AI: DRES-POCAI: A Trial Protocol.JAMA network open · 2025Article
- Comparison of Validity and Reliability of Manual Consensus Grading vs. Automated AI Grading for Diabetic Retinopathy Screening in Oslo, Norway: A Cross-Sectional Pilot Study.Journal of clinical medicine · 2025Article
- A Comprehensive Review of Explainable Artificial Intelligence (XAI) in Computer Vision.Sensors (Basel, Switzerland) · 2025Review
- Patient acceptance of AI-assisted diabetic retinopathy screening in primary care: findings from a questionnaire-based feasibility study.Frontiers in medicine · 2025Article
- The Utility of ChatGPT in Diabetic Retinopathy Risk Assessment: A Comparative Study with Clinical Diagnosis.Clinical ophthalmology (Auckland, N.Z.) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Retrospective studies on artificial intelligence (AI) in screening for diabetic retinopathy (DR) have shown promising results in addressing the mismatch between the capacity to implement DR screening and increasing DR incidence. This review sought to evaluate the diagnostic test accuracy (DTA) of AI in screening for referable diabetic retinopathy (RDR) in real-world settings. We searched CENTRAL, PubMed, CINAHL, Scopus, and Web of Science on 9 February 2023. We included prospective DTA studies assessing AI against trained human graders (HGs) in screening for RDR in patients with diabetes. Two reviewers independently extracted data and assessed methodological quality against QUADAS-2 criteria. We used the hierarchical summary receiver operating characteristics (HSROC) model to pool estimates of sensitivity and specificity and, forest plots and SROC plots to visually examine heterogeneity in accuracy estimates. From our initial search results of 3899 studies, we included 15 studies comprising 17 datasets. Meta-analyses revealed a sensitivity of 95.33% (95%CI: 90.60-100%) and specificity of 92.01% (95%CI: 87.61-96.42%) for patient-level analysis (10 datasets, N = 45,785) while, for the eye-level analysis, sensitivity was 91.24% (95%CI: 79.15-100%) and specificity, 93.90% (95%CI: 90.63-97.16%) (7 datasets, N = 15,390). Subgroup analyses did not provide variations in the diagnostic accuracy of country classification and DR classification criteria. However, a moderate increase was observed in diagnostic accuracy in the primary-level healthcare settings: sensitivity of 99.35% (95%CI: 96.85-100%), specificity of 93.72% (95%CI: 88.83-98.61%) and, a minimal decrease in the tertiary-level healthcare settings: sensitivity of 94.71% (95%CI: 89.00-100%), specificity of 90.88% (95%CI: 83.22-98.53%). Sensitivity analyses did not show any variations in studies that included diabetic macular edema in the RDR definition, nor studies with ≥3 HGs. This review provides evidence, for the first time from prospective studies, for the effectiveness of AI in screening for RDR in real-world settings. The results may serve to strengthen existing guidelines to improve current practices.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.